Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Novartis Pharmaceuticals
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- Lp(a)HORIZON
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 8323
- sponsor
- Novartis Pharmaceuticals
- conditions
- Cardiovascular Disease and Lipoprotein(a)
- interventions
- DRUG: TQJ230; DRUG: Placebo
- start date
- 2019-12-12
- start date type
- ACTUAL
- primary completion date
- 2026-07-16
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04023552
- Published
- Jul 17, 2019
- Updated
- Aug 28, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04023552
- Categories
- Cardiovascular Disease and Lipoprotein(a)
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials